Akeso shares slump despite second China approval for lung cancer drug
- Posted on April 28, 2025
- By South China Morning Post
- 5 Views
Akeso shares slump despite second China approval for lung cancer drug
Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase three trial.
